Compare Freeport-McMoRan Inc (FCX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs TransMedics Group Inc — how do they compare? Freeport-McMoRan Inc trades at $58.61 (market cap $87.65B), while TransMedics Group Inc trades at $77.03 (market cap $2.61B). The key difference: Freeport-McMoRan Inc is far larger — about 33.6× TransMedics Group Inc's market cap, and Freeport-McMoRan Inc pays a 0.98% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| FCX | TMDX | |
|---|---|---|
Market Cap | $87.65B | $2.61B |
Sector | Basic Materials | Technology |
52-Week High | $71.73 | $150.42 |
52-Week Low | $35.34 | $61.99 |
Enterprise Value | $94.31B | $3.01B |
Dividend Yield | 0.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freeport-McMoRan (FCX) trades at $61.97, up 3.33% with a bearish technical signal despite three consecutive quarterly earnings beats. The copper miner shows improving fundamentals with revenue growth to $25.92B and net income of $2.20B in 2025, supported by strong copper demand. Analyst consensus remains bullish with a $72.94 price target, though the stock faces technical resistance near $63-64 levels.
FCX presents a compelling value proposition with expanding profit margins and strategic positioning in the copper market, though investors face volatility risks from commodity price fluctuations and ongoing negative cash flow trends. The company's expansion pipeline and dividend payments provide additional shareholder value drivers.
TransMedics (TMDX) trades at $77.46, up 3.85% on the day, with a bullish technical signal and strong analyst support. The company reported robust profitability with a 27.04% net margin and 45.22% ROE, though recent Q1 2026 earnings missed expectations. Strategic expansion into Europe via the PAD Aviation investment aims to strengthen its organ transplant logistics network, a key competitive advantage. The stock's valuation metrics include a P/E of 17.25 and P/S of 4.7.
The outlook remains positive with a $108.71 consensus price target (40% upside), supported by 9 buy ratings. Key opportunities include market share gains and European expansion, while risks involve margin pressure from investments and competitive threats. Execution on growth initiatives amid decelerating revenue growth will be critical for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
